Newsfeeds - Spark Newswire

1 minute read

Analyst Ratings

Raymond James Maintains Outperform Rating for Intercept Pharmaceuticals: Here’s What You Need To Know

Today, 7:42 AM

Raymond James has decided to maintain its Outperform rating of Intercept Pharmaceuticals (NASDAQ:ICPT) and raise its price target from $26.00 to $28.00. Shares of Intercept Pharmaceuticals are trading up 2.25% over the last 24 hours, at $18.14 per share.

ICPT

1 minute read

General Motors, Foot Locker And Some Other Big Stocks Recording Gains On Friday

By Lisa Levin

Today, 7:42 AM

GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday.

AXSM

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

Today, 7:42 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

1 minute read

Intercept Settles Ocaliva Litigation With Reddy’s Lab

By Vandana Singh

Today, 7:42 AM

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE:RDY). The litigation concerns…

ICPT

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

Today, 7:42 AM

BIIB

2 minute read

Analyst Ratings

Where Intercept Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 7:42 AM

Within the last quarter, Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings:

ICPT

1 minute read

Raymond James Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target to $26

By Benzinga Newsdesk

Today, 7:42 AM

Raymond James analyst Steven Seedhouse maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and raises the price target from $23 to $26.

ICPT

1 minute read

Intercept Shares Jump After Reissuing Annual Guidance

By Vandana Singh

Today, 7:42 AM

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) completed the sale of its international business for $405 million in upfront consideration.

ICPT

1 minute read

Intercept Pharmaceuticals: Q2 Earnings Insights

By Benzinga Insights

Today, 7:42 AM

Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

ICPT

1 minute read

Intercept Pharmaceuticals Q2 EPS $(0.25) Up From $(0.33) YoY, Sales $100.40M Beat $95.72M Estimate

By Benzinga Newsdesk

Today, 7:42 AM

Intercept Pharmaceuticals (NASDAQ:ICPT) reported quarterly losses of $(0.25) per share. This is a 24.24 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly